Skip to main content
All lobbying filings

DLA PIPER LLP (US)

DLA PIPER LLP (US) filed a Q2 report for CURRAX PHARMACEUTICALS LLC on July 20, 2026, reporting $50,000 in lobbying income.

Lobbying for CURRAX PHARMACEUTICALS LLC · Specialty pharmaceutical business

All filings by DLA PIPER LLP (US) · Everything CURRAX PHARMACEUTICALS LLC has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Tennessee

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Pharmacy

Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.

 Bills named in this filing 2
  • H.R. 4231
    Treat and Reduce Obesity Act of 2025
  • S. 1973
    Treat and Reduce Obesity Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem